The largest database of trusted experimental protocols

6 protocols using rat igg2b isotype control ltf 2

1

Multiparameter Flow Cytometry Analysis of Germinal Center B Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Spleen and lymph nodes were isolated and mashed into media containing
2% FCS. For analysis of GC B cells, cells were stained with anti-B220
(RA3-6B2; BD Biosciences or Biolegend); anti-CD19 (6D5; BD Biosciences);
anti-Fas (Jo2; BD Biosciences); anti-IgD (11-26c.2a; BD Biosciences or
Biolegend); anti-CD45.1 (A20; BD Biosciences or Biolegend); anti-CD45.2 (104; BD
Biosciences or Biolegend); anti-IgG2b (RMG2b-1; BD Biosciences); homemade
Alexa647 conjugated DEL; antibody to T cell and B cell activation antigen (GL7;
BD Biosciences); anti-Mouse Eα52-68 peptide bound to I-Ab(Y-Ae, eBioscience); anti-integrin β1 (MB1.2; Chemicon); anti-integrin
β2 (C71/16; BD Biosciences); anti-integrin β3 (2C9.G2;
Biolegend); anti-integrin β7 (M293; BD Biosciences); anti-integrin
α4 (PS/2; Bio X Cell); anti-integrin αL (M17/4; Bio X
Cell); anti-integrin αV (RMV-7; BD Biosciences); rat IgG2a
isotype control (2A3; Bio X Cell); rat IgG2b isotype control (LTF-2; Bio X Cell)
or rat IgG1 isotype control (R3-34; BD Biosciences). BrdU staining was done
using BrdU flow kit (BD Biosciences) following manufacturer's
instructions. For intracellular staining of phosphorylated AKT at Ser473 (pAKT),
cells were instantly fixed and stained as described (35 (link)). Anti-pAKT (9271; Cell Signaling Technology) was
used.
+ Open protocol
+ Expand
2

Evaluating T Cell-Mediated Immunity in Viral Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
All mouse experiments were performed at OHSU in ABSL3 laboratories in compliance with OHSU IACUC protocols. The small lab animal unit at OHSU is accredited by the Association for the Accreditation and Assessment of Laboratory Animal Care (AALAC) International. Animals were housed in ventilated racks and monitored daily by veterinary staff. C57BL/6J mice were vaccinated as indicated with MCMV delivered intraperitoneally (106 PFU, i.p.), and/or AdV injected intramuscularly in the thigh (108 PFU, i.m.). Mice were challenged with 103 PFU CHIKV in a 20 μl volume in the footpad (f.p.), or they were challenged (i.m.) with 103 or 104 PFU in a 20 μl volume in the calf muscle. Footpad measurements were taken with calipers. For T cell depletion experiments, mice were administered T cell depleting antibodies diluted in PBS in a 100 μl volume (i.p.). Vaccinated groups were injected with 300 μg anti-CD4 (GK1.5, BioXCell), 300 μg anti-CD8 (2.43, BioXCell), 300 μg Rat IgG2b Isotype Control (LTF-2, BioXCell), or a combination of 300 μg anti-CD4 and 300 μg anti-CD8. T cell depletions were confirmed by flow cytometry. To confirm T cell depletions, splenocytes were stained with fluorophore-conjugated antibodies specific for mouse CD3, CD4, CD8, and CD19. Fluorescent markers were detected on an LSRII instrument (BD Pharminogen) and data was analyzed using FlowJo (TreeStar).
+ Open protocol
+ Expand
3

Anti-α4 Antibody Treatment in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mice received 200 μg of rat anti-α4 antibody (PS/2) or rat IgG2b isotype control (LTF-2) (both BioXCell) i.p. on days 4, 7 and 10 after immunization.
+ Open protocol
+ Expand
4

Murine and Human Cytokine Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
Murine GM-CSF (#315-03), human GM-CSF (#300-03), murine G-CSF (#AF-250-05), were from Peprotech. BSA (#A-7970), Ova (#A5503) anti-BSA rabbit antibody (#B7276) and anti-Ova rabbit antibody (#C6534) were from Sigma Aldrich. FITC-Ova (#O23020) was from Thermofisher). NIP-Ova (11 NIPs per Ova) was from Biosearch Technologies and anti-NIP human IgG1 (chimeric antibody with lambda light mouse chains and heavy human chains) were a gift from Richard Blumberg (Brigham and Women’s Hosp, Boston). H-2 Kb Ova Tetramer (Ova257–264) were from the NIH Tetramer Core Facility. Anti-FcγRIIIB (3G8) (Biolegend) was conjugated to FITC-Ova (#O23020, Thermofisher) as a custom order (Biolegend). Accutase cell detachment solution (#07920) was from STEMCELL Technologies. FACS antibodies used, including catalog numbers, clones, and dilutions, are in Supplementary Tables 36. For depletion experiments, anti-mouse Ly6G (1A8, #BP0075-1), anti-mouse CD4 (GK1.5, #BE0003), anti-mouse CD8 (2.43, #BE0061) and rat IgG2a isotype control (2A3, #BP0089) and rat IgG2b Isotype control (LTF-2, #BE0090) were obtained from BioXCell. Ova peptide SIINFEKL, (OTI peptide), and Ova peptide (323–339) (OTII peptide) were provided by the Partners peptide/protein core facility (Boston, MA), Diphtheria toxin (Cat #D0564) and tetanus toxoid (#582231) were from Calbiochem.
+ Open protocol
+ Expand
5

Macrophage and CD8+ T Cell Depletion in Murine Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
For macrophage depletion experiments, mice bearing KPC1245 tumors were treated with 50 mg/kg of anti-CSF1R antibody (clone AFS 98, BioXcell), administered intraperitoneally, every alternate day, until tumors were harvested on day 15. For CD8 depletion experiments, mice with KPC1245 tumors were treated with 200 μg of anti-CD8 (clone YTS169.4) or an isotype rat IgG2b control (LTF-2) from Bio-X-Cell administered intraperitoneally on day −3, 0, 3, 6, and 10 of tumor inoculation as described previously (20 (link)).
+ Open protocol
+ Expand
6

Macrophage and CD8 Depletion in KPC1245 Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
For macrophage depletion experiments, mice bearing KPC1245 tumors were treated with 50 mg/kg of anti-CSF1R antibody (clone AFS 98, BioXcell, administered intraperitoneally, every alternate day, until tumors were harvested on day 15. For CD8 depletion experiments, mice with KPC1245 tumors were treated with 200μg of anti-CD8 (clone YTS169.4) or an isotype rat IgG2b control (LTF-2) from Bio-X-Cell administered ip on day −3, 0, 3, 6 and 10 of tumor inoculation as described before (20 (link)).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!